Skip to main content
ARS Home » Research » Publications at this Location » Publication #155845
Title: RECOMBINANT PARAMYXOVIRUS TYPE 1-AVIAN INFLUENZA-H7 VIRUS AS A VACCINE FOR PROTECTION OF CHICKENS AGAINST INFLUENZA AND NEWCASTLE DISEASE

Author
item Swayne, David
item Suarez, David
item SCHULTZ-CHERRY, STACEY - UNIV OF WISCONSIN
item Tumpey, Terrence
item King, Daniel
item NAKAYA, T - MT SINAI, NEW YORK, NY
item PALESE, P - MT SINAI, NEY YORK, NY
item GARCIA-SASTRE, A - MT SINAI, NEW YORK, NY

Submitted to: Avian Diseases
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 10/27/2003
Publication Date: 10/27/2003
Citation: Swayne, D.E., Suarez, D.L., Schultz-Cherry, S., Tumpey, T., King, D.J., Nakaya, T., Palese, P., Garcia-Sastre, A. 2003. Recombinant Paramyxovirus Type 1-Avian Influenza-H7 Virus as a Vaccine for Protection of Chickens Against Influenza and Newcastle Disease. Avian Diseases 47(3):1047-1050, 2003.

Interpretive Summary:

Technical Abstract: Current vaccines to prevent avian influenza rely upon labor-intensive parenteral injection. A more advantageous vaccine would be capable of administration by mass immunization methods such as spray or water vaccination. A recombinant vaccine (rNDV-AIV-H7) was constructed by using a lentogenic Paramyxovirus type 1 vector (Newcastle disease virus [NDV] B1 strain) with insertion of the hemagglutinin (HA) gene from avian influenza virus (AIV) A/chicken/NY/13142-5/94 (H7N2). The recombinant virus had stable insertion and expression of the H7 AIV HA gene as evident by detection of HA expression via immunofluorescence in infected Vero cells. The rNDV-AIV-H7 replicated in 9-10 day embryonating chicken eggs and exhibited hemagglutinating activity from both NDV and AI proteins that was inhibited by antisera against both NDV and AIV H7. Groups of 2-week-old white Leghorn chickens were vaccinated with transfectant NDV vector (tNDV), rNDV-AIV-H7 or sterile allantoic fluid and were challenged 2 weeks later with viscerotropic velogenic NDV (vvNDV) or highly pathogenic (HP) AIV. The sham-vaccinated birds were not protected from vvNDV or HP AIV challenge. The transfectant NDV vaccine provided 70% protection for NDV challenge but did not protect against AIV challenge. The rNDV-AIV-H7 vaccine provided partial protection (40%) from vvNDV and HP AIV challenge. The serologic response was examined in chickens that received one or two immunizations of the rNDV-AIV-H7 vaccine. Based on hemagglutination inhibition and ELISA tests, chickens that received a vaccine boost seroconverted to AIV H7, but the serologic response was weak in birds that received only one vaccination. This demonstrates the potential for NDV for use as a vaccine vector in expressing AIV proteins.